Work

P2.09-18 FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions

Year: 2023

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.592

Authors: A.I. Spira, B.C. Cho, E. Felip, E.B. Garon, K. Goto, M.L. Johnson, N.B. Leighl, A. Passaro, D. Planchard, S. Popat, J. Yang, X. Lu, Y. Jiang, J. Huang, M. Lam, M. Kowanetz, S. Wang, J. Le, J.Y. Hsu, C. Zhou

Institutions: Virginia Cancer Specialists, Yonsei University, Yonsei Cancer Hospital, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of California, Los Angeles, National Cancer Center Hospital East, Sarah Cannon, Princess Margaret Cancer Centre, European Institute of Oncology, Institut Gustave Roussy, Fondation Gustave Roussy, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, National Taiwan University Hospital, Shanghai Pulmonary Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388045717

FWCI: 0.159

Cites:

Cited by: 1

Related to: 10